Moderna's experimental flu vaccine — built on the same messenger RNA technology that reshaped the COVID-19 pandemic response — has cleared a major regulatory milestone. On June 18, 2026, the FDA's top vaccine advisory committee voted 9-0 to recommend the vaccine, called mFlusiva, for adults aged 50 and older.
The unanimous vote by the Vaccines and Related Biological Products Advisory Committee (VRBPAC) sets the stage for what would be the first mRNA-based seasonal influenza vaccine ever approved in the United States. The FDA's final decision is expected by August 5, 2026 — potentially in time to make the vaccine available this coming fall.
Why This Matters
Flu is not a minor inconvenience. According to data presented to the FDA panel by the CDC's Dr. Lisa Grohskopf, the 2025–2026 flu season produced at least 32 million illnesses, 390,000 hospitalizations, and 24,000 deaths in the United States. She noted that approximately 85 percent of those eligible for vaccination were not fully vaccinated against influenza.
The mRNA platform offers two potential advantages over traditional flu vaccines: faster production timelines and, based on the data reviewed by the panel, stronger protection against severe illness. Both could matter significantly if a new or more virulent flu strain emerges mid-season.
What We Know So Far
The FDA panel's two-part vote covered two age groups separately: adults 50 to 64 years old (where Moderna seeks standard approval) and adults 65 and older (where Moderna seeks accelerated approval, with a post-marketing confirmatory trial required). Both votes resulted in unanimous support — 9-0 each.
The approval pathway reflects a key difference in what the evidence shows. For adults 50 to 64, Moderna demonstrated traditional clinical efficacy. For adults 65 and older, the FDA's current recommendation is already a high-dose or adjuvanted vaccine rather than a standard-dose option — so Moderna's approval for that age group is based on superior immune response (immunogenicity), not a direct efficacy comparison.
In Moderna's Phase 3 efficacy study of 40,805 participants, mFlusiva showed a 26.6 percent higher relative vaccine efficacy against confirmed flu illness compared to a standard-dose flu shot. When measuring severe healthcare outcomes — emergency room visits, hospitalizations, and urgent care — efficacy rose to 47.9 percent relative to the standard comparator.
Where the Impact Would Be Greatest
The vaccine, if approved, would be most relevant for American adults aged 50 and older — a group of approximately 120 million people that accounts for the vast majority of flu-related deaths and hospitalizations each year.
Major metropolitan areas with large populations of older adults — including Miami, Philadelphia, New York City, Chicago, Phoenix, and Boston — would stand to benefit the most from a more effective flu vaccine, particularly one that can be produced faster and potentially better matched to circulating strains.
One key advantage of the mRNA platform that resonated with panelists: speed. Moderna noted that mRNA technology can shorten the time needed to produce a strain-matched vaccine from roughly six months to two to three months, similar to what was achieved with COVID-19 vaccines. This flexibility could be critical if flu surveillance detects a poorly matched strain late in the season.
What Doctors and Experts Say
Dr. Flor Munoz-Rivas, associate professor of pediatrics and infectious disease at Baylor College of Medicine and a VRBPAC panelist, stated during the meeting: "The studies that were presented today were very well conducted. They have very clear results that are very robust." She added that approval would leave the United States better prepared for emerging or pandemic influenza strains.
Dr. Paul Offit, director of the Vaccine Education Center at Children's Hospital of Philadelphia and a former advisory committee member, called the panel's vote encouraging. "It's such a breath of fresh air, considering what we've gone through with Robert F. Kennedy Jr.," he told NPR.
Meanwhile, panel member Dr. Adam Berger said the evidence broadly supports the safety and effectiveness of the vaccine and that the safety data were relatively reassuring, while acknowledging some limitations in the trial design.
What the Evidence Shows — and What It Does Not
The FDA's pre-meeting briefing documents identified no major deficiencies in Moderna's application. However, the agency flagged several areas of uncertainty for the panel to weigh.
All efficacy data for mFlusiva comes from a single influenza season. The vaccine's performance against different strains circulating in future seasons remains unknown. The trial also did not clearly establish efficacy against the influenza B/Victoria strain, lacked data in very frail older adults or immunocompromised individuals, and did not include co-administration data with other respiratory vaccines such as COVID-19 or RSV shots.
These gaps are expected to be addressed through post-marketing requirements if the FDA approves the vaccine.
MedicalDaily Evidence Check
- Study type: Phase 3 randomized clinical trial (P304)
- Participants: 40,805 adults aged 50 and older
- Published in: New England Journal of Medicine and Nature Immunology
- What it found: 26.6% higher relative efficacy against flu illness compared to standard-dose vaccine; 47.9% higher efficacy in preventing severe outcomes
- What it did not prove: Efficacy against B/Victoria strain; effectiveness in frail elderly or immunocompromised individuals; performance across multiple flu seasons
- What readers should know: The FDA committee found the data sufficient to recommend approval, but additional post-market study is expected
Who Faces the Greatest Risk?
The age groups most likely to benefit from a more protective flu vaccine include:
- Adults aged 65 and older, who face the highest risk of flu-related hospitalization and death
- Adults 50 to 64 with underlying conditions such as heart disease, diabetes, or weakened immune systems
- Caregivers and household members of immunocompromised individuals
- Residents in high-density urban areas or care facilities with seasonal flu exposure
People under age 50 are not included in the current advisory committee recommendation. The FDA's review focused exclusively on adults 50 and older.
What You Can Do Now
- The vaccine has not yet been approved. Continue planning to get a flu shot this fall with whatever vaccine your doctor or pharmacist recommends as the best option for your age and health status.
- Adults 65 and older are already advised by the CDC to get a high-dose or adjuvanted flu vaccine rather than a standard dose. If mFlusiva is approved, it may become an additional recommended option for that age group.
- Check with your health care provider in August or September for guidance on which flu vaccines will be available for the 2026–2027 season.
- Do not wait on flu vaccination to see whether mFlusiva is approved. Getting vaccinated with available options remains the best-proven protection.
Cost and Access: What Patients Should Know
The FDA's final approval decision is expected by August 5, 2026. However, availability for this fall season also depends on a separate step: a recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP). Without an ACIP recommendation, insurers may not be required to cover the vaccine at no cost under the Affordable Care Act. Currently, the ACIP is facing legal challenges to its reconstitution under the current administration, according to Pharmacy Times, which could delay or complicate routine coverage.
Patients should monitor updates from their insurer and health care provider as the fall season approaches.
What Happens Next
The FDA's formal decision on mFlusiva is expected on or before August 5, 2026. If approved, Moderna has said the vaccine could be available for the 2026–2027 flu season. The parallel question of insurance coverage depends on the ACIP's legal and operational status. Regulatory filings for mFlusiva are also under review in the European Union, Canada, and Australia. MedicalDaily will update this story after the FDA's final decision.
The Bottom Line
The FDA's advisory committee has unanimously endorsed Moderna's mRNA flu vaccine for adults 50 and older, backed by data from more than 40,000 trial participants. If the FDA approves the vaccine by August 5, it could offer older Americans a more effective flu shot option as early as this fall — and could make the United States better positioned to respond to future pandemic-level flu threats. For now, adults should continue to plan for a flu shot in September or October with currently available vaccines.
References
- NPR — FDA Committee Recommends a New mRNA Flu Vaccine
- BioPharma Dive — Moderna Flu Vaccine Wins Unanimous Support From FDA Panel
- BioPharm International — FDA Advisory Panel Votes 9-0 in Favor of Moderna's mRNA Flu Vaccine
- Fierce Biotech — Moderna's Flu Candidate Sails Through FDA Advisory Committee
- Pharmacy Times — FDA Panel Unanimously Backs Moderna's mRNA Flu Vaccine
